Viral Inactivation Market Share, Analysis, Outlook, Overview, Forecast 2024 - 2033

"The new report published by The Business Research Company, titled Viral Inactivation Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the viral inactivation market size has grown strongly in recent years. It will grow from $4.54 billion in 2023 to $4.98 billion in 2024 at a compound annual growth rate (CAGR) of 9.7%. The viral inactivation market size is expected to see rapid growth in the next few years. It will grow to $7.32 billion in 2028 at a compound annual growth rate (CAGR) of 10.1%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=10401&type=smp

Rising Prevalence Of Infectious Diseases To Drive Market Growth
Growing instances of various infectious diseases are expected to propel the growth of the viral inactivation market, going forward. Infectious diseases refer to the conditions that transmit from one individual to another, via polluted foods and beverages, and through pathogens such as viruses, bacteria, fungi, and parasites. Viral inactivation is widely applicable in human disease-control programs to inactivate viruses using physical and chemical disinfectants to prevent the spread of contagious viral infections, resulting in the growth of the viral inactivation market. For instance, in December 2022, according to the 'Annual Epidemiological Report for 2021', published by European Centre for Disease Prevention and Control, a Sweden-based, European Government Health Agency, 2021, the distribution of hepatitis C cases and rates per 100,000 population, in Germany, reached 4,718 cases and 5.7 rates respectively from 4,536 cases 5.5 rates in 2020. Therefore, the growing instances of various infectious diseases are driving the growth of the viral inactivation market.

Technological Advancements Driving Innovation In Viral Inactivation Market
The increasing use of technologically advanced processes is a key trend gaining popularity in the viral inactivation market. Companies operating in the viral inactivation market are adopting technologically advanced processes to sustain their position in the market. For instance, in March 2022, WuXi Advanced Therapies, a wholly owned subsidiary of WuXi AppTec, a China-based, biopharmaceutical company, launched Tetracycline-Enabled Self-Silencing Adenovirus (TESSA) Technology. This cutting-edge technology has enabled, the approval of new therapies by conducting all assay formulation, biosafety, viral clearance, product release, and testing, done simultaneously, in-house. This technique is a novel innovative method for producing adeno-associated virus (AAV) at Good Manufacturing Practices (GMP) grade without the need for transfection.

The viral inactivation market covered in this report is segmented -

1) By Product: Kits And Reagents, Systems, Services
2) By Method: Solvent Detergent Method, pH Adjustment Method, Pasteurization, Other Methods
3) By Application: Vaccines And Therapeutics, Tissues And Tissue Products, Blood And Blood Products, Other Applications
4) By End User: Pharmaceutical And Biotechnology Companies, Contract Research Organizations, Blood Banks, Hospital, Academic Research Institutes, Other End Users

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=10401&type=discount

Major companies operating in the viral inactivation market report are Merck & Co. Inc., PARKER HANNIFIN CORP., Sartorius AG, Texcell SA, SGS SA, Charles River Laboratories Inc., Clean Cells SAS, Rad Source Technologies, WuXi AppTec, Sigma-Aldrich Co. LLC, Thermo Fisher Scientific Inc., Macopharma, Cerus Corporation, TERUMO BCT INC., Shandong Weigao Group Medical Polymer Co. Ltd., SCI Automation Pte. Ltd., Pall Corporation And Eurofins Scientific, General Electric Company, Cytiva, Mettler Toledo, Viral Inactivated Plasma Systems SA, Eurofins Scientific SE, Lonza Group AG, Avantor Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche AG, Fujifilm Holdings Corporation, Pfizer Inc., Novartis AG, Gilead Sciences Inc., Johnson & Johnson Private Limited

Contents of the report:
1. Executive Summary
2. Viral Inactivation Market Report Structure
3. Viral Inactivation Market Trends And Strategies
4. Viral Inactivation Market - Macro Economic Scenario
5. Viral Inactivation Market Size And Growth
…..
27. Viral Inactivation Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/viral-inactivation-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

"Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide."

This release was published on openPR.